Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Debt to Equity: 2023-2025

Historic Debt to Equity for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$0.03.

  • BioLineRx's Debt to Equity rose 62.72% to -$0.03 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.03, marking a year-over-year increase of 62.72%. This contributed to the annual value of -$0.03 for FY2024, which is 234.32% down from last year.
  • BioLineRx's Debt to Equity amounted to -$0.03 in Q2 2025, which was up 9.99% from -$0.03 recorded in Q1 2025.
  • BioLineRx's 5-year Debt to Equity high stood at $0.03 for Q4 2023, and its period low was -$0.08 during Q2 2024.
  • Its 3-year average for Debt to Equity is -$0.03, with a median of -$0.03 in 2023.
  • Its Debt to Equity has fluctuated over the past 5 years, first slumped by 234.32% in 2024, then skyrocketed by 62.72% in 2025.
  • Quarterly analysis of 3 years shows BioLineRx's Debt to Equity stood at $0.03 in 2023, then tumbled by 234.32% to -$0.03 in 2024, then soared by 62.72% to -$0.03 in 2025.
  • Its Debt to Equity stands at -$0.03 for Q2 2025, versus -$0.03 for Q1 2025 and -$0.03 for Q4 2024.